ELVN

Enliven TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$58.00

+63.3% vs current

Most likely

Base case

45%

Probability

Target price

$38.00

+7.0% vs current

B-

Bear case

30%

Probability

Target price

$24.00

-32.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Current sentiment looks cautious rather than outright bullish. The March 3, 2026 primary-source update gave investors a credible 2026 milestone map and a long runway, but the evidence set is still dominated by company-guided clinical milestones rather than external validation or broadened coverage [#PR-2026-03-03] [#8-K-2026-03-03] [#10-K-2026-03-03]. With deterministic signals negative and catalyst density modest, this reads more like a monitoring setup around upcoming ELVN-001 execution than a high-conviction upside call.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventAdditional Phase 1 ENABLE data mid-2026High impact

Management guided to a mid-year presentation of additional Phase 1 data from the ongoing ENABLE trial for ELVN-001; that dataset is the next concrete de-risking checkpoint after the initial Phase 1b update, with timing inferred from the company’s 'mid-year' language [#PR-2026-03-03].

2026-09-30eventFDA alignment on dose selection and Phase 3 designHigh impact

Enliven said 2026 should include regulatory alignment with the FDA on dose selection and Phase 3 trial design for ELVN-001; that interaction matters because the company is still converting promising early data into a registrational path, with date inferred from 2026 company guidance [#PR-2026-03-03] [#10-K-2026-03-03].

2026-11-15catalystENABLE-2 Phase 3 initiation in second half of 2026High impact

The company plans to initiate ENABLE-2, a 2L+ Phase 3 pivotal trial of ELVN-001, in the second half of 2026; successful start would be the clearest proof that ELVN-001 is moving into late-stage development, but delay would likely pressure sentiment, with date inferred from 'second half of 2026' guidance [#PR-2026-03-03] [#10-K-2026-03-03].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology